Alnylam Pharmaceuticals, Inc. (ALNY) ist ein börsennotiertes Unternehmen im Gesundheitswesen Sektor, tätig in der Biotechnologie Branche. Der Hauptsitz des Unternehmens ist in Cambridge, MA, United States. Der aktuelle CEO ist Yvonne L. Greenstreet.
ALNY hat IPO-Datum 2004-06-01, 2,230 Vollzeitbeschäftigte, gelistet an der NASDAQ Global Select, eine Marktkapitalisierung von $45.01B.
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing novel RNAi (RNA interference) therapeutics for genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and CNS/ocular diseases. The company has three marketed products: ONPATTRO for hereditary transthyretin amyloidosis, GIVLAARI for acute hepatic porphyria, and OXLUMO for primary hyperoxaluria type 1. Alnylam maintains a robust pipeline of investigational therapies addressing hemophilia, hypertension, hypercholesterolemia, and metabolic liver disease, supported by strategic collaborations with Regeneron Pharmaceuticals and Sanofi Genzyme. Founded in 2002 and headquartered in Cambridge, Massachusetts, the company has established multiple license and collaboration agreements with leading pharmaceutical organizations to advance RNAi-based drug development.
